In This Article:
The Australian stock market recently demonstrated resilience, with the ASX climbing above the 7,800 points level despite mixed performances in global markets. In such a landscape, investors often seek out smaller or newer companies that can offer unique growth opportunities. Although "penny stocks" may sound like an outdated term, these stocks represent potential value investments; when backed by strong financials and fundamentals, they can provide significant upside potential.
Top 10 Penny Stocks In Australia
Name | Share Price | Market Cap | Financial Health Rating |
CTI Logistics (ASX:CLX) | A$1.57 | A$122.48M | ★★★★☆☆ |
MotorCycle Holdings (ASX:MTO) | A$2.10 | A$154.99M | ★★★★★★ |
EZZ Life Science Holdings (ASX:EZZ) | A$1.58 | A$74.53M | ★★★★★★ |
IVE Group (ASX:IGL) | A$2.35 | A$362.33M | ★★★★★☆ |
GTN (ASX:GTN) | A$0.60 | A$115.38M | ★★★★★★ |
Bisalloy Steel Group (ASX:BIS) | A$3.19 | A$151.37M | ★★★★★★ |
Regal Partners (ASX:RPL) | A$1.795 | A$603.41M | ★★★★★★ |
Sugar Terminals (NSX:SUG) | A$1.10 | A$363.6M | ★★★★★★ |
NRW Holdings (ASX:NWH) | A$2.47 | A$1.13B | ★★★★★☆ |
LaserBond (ASX:LBL) | A$0.3825 | A$44.88M | ★★★★★★ |
Click here to see the full list of 982 stocks from our ASX Penny Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Dimerix
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Dimerix Limited is a biopharmaceutical company based in Australia that focuses on developing and commercializing pharmaceutical products to address unmet medical needs, with a market cap of A$237.68 million.
Operations: Dimerix generates revenue primarily from its biotechnology segment, amounting to A$0.74 million.
Market Cap: A$237.68M
Dimerix Limited, with a market cap of A$237.68 million, is pre-revenue, generating only A$0.74 million in revenue from its biotechnology segment. The company reported a net loss of A$12.91 million for the half-year ending December 2024, an increase from the prior year. Despite being debt-free and having experienced management and board members, Dimerix faces challenges with less than a year of cash runway if current cash flow trends persist. Its addition to the S&P/ASX All Ordinaries Index reflects some market recognition despite its financial hurdles and high volatility stability over the past year.
-
Click here to discover the nuances of Dimerix with our detailed analytical financial health report.
-
Understand Dimerix's track record by examining our performance history report.
Sovereign Metals
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Sovereign Metals Limited, with a market cap of A$425.91 million, is involved in the exploration and development of mineral resource projects in Malawi.